Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company developing oral anti-infective therapies, with lead candidate MAT2203 showing promise in treating invasive fungal infections. Recent developments include leadership changes, fundraising, and strategic shifts, amid setbacks like workforce reduction and paused product development. The company focuses on restructuring and resource management, with collaborations to develop new drug formulations and delivery methods. While MTNB offers investment potential, certain AI stocks may provide greater upside and less risk.

Read more at Yahoo Finance: Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203